Skip to main content
BioGaia logo

BioGaia — Investor Relations & Filings

Ticker · BIOG ISIN · SE0017769995 LEI · 549300UBUJOY2L7TT361 ST Manufacturing
Open in API
Filings indexed 610 across all filing types
Latest filing 2022-07-22 Interim / Quarterly Rep…
Country SE Sweden
Listing ST BIOG

About BioGaia

https://www.biogaia.com/

BioGaia is a healthcare and biotechnology company that is a world leader in probiotics. A pioneer in microbiome research for over 30 years, the company develops, markets, and sells a range of clinically proven probiotic products. Its portfolio is centered on its patented probiotic strain, Lactobacillus reuteri. These products, typically offered as food supplements, are designed to support the health and well-being of consumers at all stages of life.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport' (Interim Report) for the period January–June 2022. It contains comprehensive financial statements, including income statements, cash flow analysis, segment reporting, and management commentary on business performance. It is not a short announcement or a certification, but the full interim financial report itself, which fits the definition of an Interim/Quarterly Report (IR). H2 2022
2022-07-22 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled 'Interim Report' and covers the period from January to June 2022. It contains detailed financial statements, including net sales, operating profit, earnings per share, and cash flow data for the second quarter and the first half of the year. It also includes management commentary (CEO's comments) and segment-level financial breakdowns. It is not a mere announcement or certification, but the substantive financial report itself, fitting the definition of an Interim/Quarterly Report (IR). H1 2022
2022-07-22 English
BioGaia’s result for second quarter to exceed market expectations
Earnings Release Classification · 100% confidence The document provides preliminary financial highlights for the second quarter, including estimated sales and operating profit figures, and explicitly states the date and time the full interim report will be published. The text is very short (1240 characters) and focuses on announcing the results ahead of the full report release. This structure—preliminary results announcement followed by the date of the comprehensive report—is characteristic of an Earnings Release (ER). It is not the full Interim Report (IR) itself, nor is it a general announcement about publishing a report (RPA), as it contains the key figures. The mention of 'interim report for the second quarter' confirms the periodicity, but the content is the initial release of those results. Q2 2022
2022-07-14 English
BioGaias resultat för andra kvartalet överstiger marknadens förväntningar
Earnings Release Classification · 100% confidence The document is a short press release written in Swedish announcing preliminary financial results for the second quarter (Q2 2022). Key phrases include 'resultat för andra kvartalet' (results for the second quarter), preliminary sales figures ('försäljningen preliminärt uppgå till cirka 288 miljoner kronor'), and a specific date for the full report release ('BioGaia publicerar delårsredogörelsen för kvartal två fredagen den 22 juli 2022'). Since this is the initial announcement of key periodical financial results, it fits the definition of an Earnings Release (ER). It is not the comprehensive report itself (which would be IR), nor is it an announcement about the publication of a report (RPA), as it contains the actual preliminary results. Filing Type Code: ER (Earnings Release). Q2 2022
2022-07-14 Swedish
New number of shares and votes in BioGaia AB (publ)
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces a change in the 'New number of shares and votes' following a share split resolved by the Annual General Meeting. It details the new total number of shares (100,982,310) and the corresponding votes as of May 31, 2022. This directly relates to a change in the company's capital structure (share count/split). The most appropriate classification among the provided options is 'Share Issue/Capital Change' (SHA), as a share split is a capital structure change. It is not a general regulatory filing (RNS) because it fits a more specific category, nor is it a dividend announcement (DIV) or a transaction in own shares (POS), as it describes the result of a pre-approved split.
2022-05-31 English
Förändrat antal aktier och röster i BioGaia AB (publ)
Share Issue/Capital Change Classification · 99% confidence The document is a short announcement (1393 characters) titled "Förändrat antal aktier och röster i BioGaia AB (publ)" (Changed number of shares and votes in BioGaia AB (publ)). It explicitly details the result of a share split decided at the AGM, stating the new total number of shares and votes as of May 31, 2022. This directly relates to a change in the company's capital structure following a corporate action. This fits the definition of 'Share Issue/Capital Change' (SHA), which covers changes in capital structure, including splits. It is not a full report (10-K, IR), a dividend notice (DIV), or a director's dealing (DIRS). Since it is a specific announcement about a capital structure change, SHA is the most appropriate code over the general fallback RNS.
2022-05-31 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.